Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 9 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Beam Therapeutics Inc | BEAM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 24.10 | 07:39:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 24.10 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 5 | 9 | - | 16.95 - 49.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:11:16 | 2 | $ 24.30 | USD |
Beam Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.97B | 81.66M | - | 377.71M | -132.53M | -1.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Beam Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BEAM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 25.23 | 26.14 | 23.205 | 24.31 | 2,360,988 | -1.13 | -4.48% |
| 1 Month | 34.31 | 34.6759 | 23.205 | 27.15 | 1,610,329 | -10.21 | -29.76% |
| 3 Months | 28.00 | 49.50 | 23.205 | 32.36 | 1,541,603 | -3.90 | -13.93% |
| 6 Months | 17.45 | 49.50 | 16.95 | 28.87 | 1,503,344 | 6.65 | 38.11% |
| 1 Year | 31.16 | 49.50 | 16.95 | 28.66 | 1,182,819 | -7.06 | -22.66% |
| 3 Years | 74.84 | 138.5219 | 16.95 | 47.70 | 1,019,223 | -50.74 | -67.80% |
| 5 Years | 19.19 | 138.5219 | 13.00 | 50.08 | 914,084 | 4.91 | 25.59% |
Beam Therapeutics Description
| Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. |
